The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
NLRP3 inflammasome activation drives tau pathology
Open accessAbstract
Alzheimer’s disease is characterized by the accumulation of amyloid-beta in plaques, aggregation of hyperphosphorylated tau in neurofibrillary tangles and neuroinflammation, together resulting in neurodegeneration and cognitive decline1. The NLRP3 inflammasome assembles inside of microglia on activation, leading to increased cleavage and activity of caspase-1 and downstream interleukin-1β release2. Although the NLRP3 inflammasome has been shown to be essential for the development and progression of amyloid-beta pathology in mice3, the precise effect on tau pathology remains unknown. Here we show that loss of NLRP3 inflammasome function reduced tau hyperphosphorylation and aggregation by regulating tau kinases and phosphatases. Tau activated the NLRP3 inflammasome and intracerebral injection of fibrillar amyloid-beta-containing brain homogenates induced tau pathology in an NLRP3-dependent manner. These data identify an important role of microglia and NLRP3 inflammasome activation in the pathogenesis of tauopathies and support the amyloid-cascade hypothesis in Alzheimer’s disease, demonstrating that neurofibrillary tangles develop downstream of amyloid-beta-induced microglial activation. The authors show that NLRP3 inflammasome is activated in microglia of patients with fronto-temporal dementia and in a mouse model of tau pathology, and that the loss of NLRP3 inflammasome function decreases tau pathology and improves cognition in mice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The NLRP3-ASC inflammasome mechanisms contributing to increased beta-amyloids and tau are thought to be a combination of kinases and phosphatases involved in tau phosphorylation [96] through the production of IL-1 beta.”
From The Role of Cortisol in Chronic Stress, Neurodegenerative Diseases, and Psychological Disorders (2023) · cites this paper as [96]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the CNS, inflammasome activation has been mainly linked to neuroinflammatory conditions. As example, it has an essential role in the progression of several neurological disorders like MS, AD, PPD, and NPS (132, 193–197).”
From The gut-brain axis: how microbiota and host inflammasome influence brain physiology and pathology (2020) · cites this paper as [197]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The activation of hippocampal NLRP3 inflammasome-mediated pyroptosis is associated with neuronal damage, cognitive decline, and neuronal death (Hanslik & Ulland, 2020; Heneka et al., 2013; Ising et al., 2019; Venegas et al., 2017).”
From Picroside II Alleviates the Progression of Alzheimer’s Disease via the NLRP3/Caspase-1/GSDMD Pathway (2025) · cites this paper as Ising et al., 2019
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“On the other hand, treatment of mouse primary hippocampal neurons with conditioned media from wild-type, but not Nlrp3−/− and Asc−/−, microglia primed with LPS resulted in elevated total and phosphorylated tau levels, suggesting that NLRP3 inflammasome activation in microglia can induce tau pathology in neurons.”
From Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease (2023) · cites this paper as [81]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Additionally, several cytokines, including IL-1β and IL-6, can directly induce tau phosphorylation in vitro, thus potentially contributing to the development of tau pathology.54”
From Amelioration of Tau and ApoE4-linked glial lipid accumulation and neurodegeneration with an LXR agonist (2024) · cites this paper as [56]
Experimental — accuracy not yet measured
The cited source says what the claim attributes to it.
In the citing paper
“Research by Ising et al. suggests that tau proteins can activate the NLRP3 inflammasome, which then promotes excessive tau phosphorylation and aggregation by affecting specific tau kinases and phosphatases.252”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [252]
The cited source says what the claim attributes to it.
In the citing paper
“In turn, the NLRP3 inflammasome is essential for the development and progression of Aβ pathology in mice29 and may drive tau pathology through Aβ-induced microglial activation30.”
From New insights into the genetic etiology of Alzheimer’s disease and related dementias (2022) · cites this paper as [30]
The cited source says what the claim attributes to it.
In the citing paper
“A recent study shows that NLR family pyrin domain-containing protein 3 (NLRP3) inflammasome activation induces tau hyperphosphorylation and aggregation through modulating tau kinases and phosphatases [159].”
From Tau and neuroinflammation in Alzheimer’s disease: interplay mechanisms and clinical translation (2023) · cites this paper as [159]
The cited source says what the claim attributes to it.
In the citing paper
“On the other hand, microglia could also drive tau spreading and toxicity by promoting neuroinflammation, such as activating NACHT-, LRR- and pyrin (PYD)-domain-containing protein 3 (NLRP3) inflammasome155 or inducing NF-kB signaling.”
From Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets (2023) · cites this paper as [155]
The cited source says what the claim attributes to it.
In the citing paper
“Tau oligomers and monomers can also activate NLRP3 inflammasomes, further perpetuating microglial activation [162] and potential progression of tau pathology.”
From Microglia and monocytes in inflammatory CNS disease: integrating phenotype and function (2022) · cites this paper as [162]
The cited source says what the claim attributes to it.
In the citing paper
“Treatment of wild-type primary microglia with recombinant wild-type tau and recombinant tau with a P301S mutation increased IL-1β secretion, an effect that was attenuated in Nlrp3−/− and Asc−/− microglia, suggesting that tau induces IL-1β secretion in a NLRP3-dependent manner [81].”
From Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease (2023) · cites this paper as [81]
The cited source says what the claim attributes to it.
In the citing paper
“Inhibiting or downregulating the NLRP3 inflammasome ameliorates AD neuropathology in animal models, which opens up a therapeutic avenue for modulators of NLRP3 activation in AD.”
From Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease (2023) · cites this paper as [81]
The cited source says what the claim attributes to it.
In the citing paper
“On the other hand, treatment of mouse primary hippocampal neurons with conditioned media from wild-type, but not Nlrp3−/− and Asc−/−, microglia primed with LPS resulted in elevated total and phosphorylated tau levels, suggesting that NLRP3 inflammasome activation in microglia can induce tau pathology in neurons.”
From Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease (2023) · cites this paper as [81]
The cited source says what the claim attributes to it.
In the citing paper
“Treatment of wild-type primary microglia with recombinant wild-type tau and recombinant tau with a P301S mutation increased IL-1β secretion, an effect that was attenuated in Nlrp3−/− and Asc−/− microglia, suggesting that tau induces IL-1β secretion in a NLRP3-dependent manner [81].”
From Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease (2023) · cites this paper as [81]
The cited source says what the claim attributes to it.
In the citing paper
“The NLRP3 inflammasome has a bidirectional relationship with AD-related tau pathology as well.”
From Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease (2023) · cites this paper as [81]
The cited source says what the claim attributes to it.
In the citing paper
“Evidence suggests that while some forms of tau can activate the NLRP3 inflammasome, inflammasome activation can exacerbate tau pathology by promoting elevated phosphorylation of tau [81, 82].”
From Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease (2023) · cites this paper as [81]
The cited source says what the claim attributes to it.
In the citing paper
“Moreover, treatment with brain homogenates from APP/PS1 mice induced tau hyperphosphorylation in a mouse model of tau aggregation pathology (Tau22) but not in Tau22/Nlrp3−/− and Tau22/Asc−/− mice, indicating the NLRP3 inflammasome as a mediator of Aβ-induced tau pathology [81].”
From Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease (2023) · cites this paper as [81]
The cited source says what the claim attributes to it.
In the citing paper
“Moreover, treatment with brain homogenates from APP/PS1 mice induced tau hyperphosphorylation in a mouse model of tau aggregation pathology (Tau22) but not in Tau22/Nlrp3−/− and Tau22/Asc−/− mice, indicating the NLRP3 inflammasome as a mediator of Aβ-induced tau pathology [81].”
From Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease (2023) · cites this paper as [81]
The cited source says what the claim attributes to it.
In the citing paper
“Evidence suggests that while some forms of tau can activate the NLRP3 inflammasome, inflammasome activation can exacerbate tau pathology by promoting elevated phosphorylation of tau [81, 82].”
From Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease (2023) · cites this paper as [81]
The cited source says what the claim attributes to it.
In the citing paper
“In Tau22 mice, ablation of Nlrp3 or Asc reduced levels of hyperphosphorylated tau and tau aggregates and rescued tau-induced spatial memory deficits [81].”
From Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease (2023) · cites this paper as [81]
In the citing paper
“Studies have demonstrated important roles of the NLRP3 inflammasome in aging and age-related diseases, such as atherosclerosis metabolic syndrome, type 2 diabetes, and Alzheimer’s disease (81–83).”
From Connecting aging biology and inflammation in the omics era (2022) · cites this paper as [83]
In the citing paper
“For example, in AD and frontotemporal dementia, neuroinflammation and microglia activation potentiate the spreading of pathological tau neurofibrillary tangles (83, 175).”
From Connecting aging biology and inflammation in the omics era (2022) · cites this paper as [83]
In the citing paper
“In AD, this relationship may be mediated by NLRP3 inflammasome activation in microglia, a process that activates tau kinases (e.g., GSK-3β and CaMKII-α) and results in tau hyperphosphorylation (83).”
From Connecting aging biology and inflammation in the omics era (2022) · cites this paper as [83]
In the citing paper
“The knockout of ASC or NLRP3 ameliorates AD‐like brain pathology in animal models. 68”
From Senescence, brain inflammation, and oligomeric tau drive cognitive decline in Alzheimer's disease: Evidence from clinical and preclinical studies (2024) · cites this paper as [68]
In the citing paper
“The activation of the NLRP3 inflammasome drives tau pathology. 68”
From Senescence, brain inflammation, and oligomeric tau drive cognitive decline in Alzheimer's disease: Evidence from clinical and preclinical studies (2024) · cites this paper as [68]
In the citing paper
“Inflammaging can drive tau pathology and neurodegeneration in AD by impairing the clearance of Aβ peptides, altering BBB integrity, and affecting the synaptic functions. 68”
From Senescence, brain inflammation, and oligomeric tau drive cognitive decline in Alzheimer's disease: Evidence from clinical and preclinical studies (2024) · cites this paper as [68]
In the citing paper
“In general, patients affected by tauopathies showed elevated levels of cleaved caspase-1 and ASC and mature IL-1β in the cortex (197).”
From The gut-brain axis: how microbiota and host inflammasome influence brain physiology and pathology (2020) · cites this paper as [197]
In the citing paper
“Injecting brain homogenates from APP/PS1 or wild-type mice into the hippocampus of Tau22 mice, induced tau hyperphosphorylation in the hippocampus of Tau22 wild-type but not Tau22/Pycard−/− or Tau22/Nlrp3−/− deficient mice”
From The gut-brain axis: how microbiota and host inflammasome influence brain physiology and pathology (2020) · cites this paper as [197]
In the citing paper
“suggesting that NLRP3 activation is upstream the Aβ-tau cascade and tau pathology (197).”
From The gut-brain axis: how microbiota and host inflammasome influence brain physiology and pathology (2020) · cites this paper as [197]
In the citing paper
“Consistent with this, Tau22 mice lacking ASC or NLRP3 expression had lower levels of aggregated and hyperphosphorylated tau in the hippocampus, and their typical spatial memory deficits were rescued (197).”
From The gut-brain axis: how microbiota and host inflammasome influence brain physiology and pathology (2020) · cites this paper as [197]
In the citing paper
“Also, Tau22 mice, another model of AD and other tauopathies, had increased levels of cleaved caspase-1 and ASC in their brain at the age of 11 months compared to their 3-month-old counterparts.”
From The gut-brain axis: how microbiota and host inflammasome influence brain physiology and pathology (2020) · cites this paper as [197]
In the citing paper
“Further, activated microglia promote tau phosphorylation and aggregation by activation of the NLRP3 (nucleotide binding oligomerisation domain (NOD)-, leucine-rich repeat (LRR)- and pyrin domain-containing protein 3) inflammasome in response to amyloid-β [22,23].”
From ROS Generation in Microglia: Understanding Oxidative Stress and Inflammation in Neurodegenerative Disease (2020) · cites this paper as [23]
In the citing paper
“Further, there is evidence tauopathy is driven by NLRP3 inflammasome activation in microglia in response to amyloid-β [23].”
From ROS Generation in Microglia: Understanding Oxidative Stress and Inflammation in Neurodegenerative Disease (2020) · cites this paper as [23]
In the citing paper
“ROS from NOX4 also contribute to activation of the NLRP3 inflammasome, a driver of both amyloid-β [156] and tau [23] pathology.”
From ROS Generation in Microglia: Understanding Oxidative Stress and Inflammation in Neurodegenerative Disease (2020) · cites this paper as [23]
In the citing paper
“Growing evidence indicates that Aβ accumulation stimulates tau phosphorylation and fibrillary tangle formation, leading to the process of neurodegeneration.112–114”
From Amyloid β-based therapy for Alzheimer’s disease: Challenges, successes and future (2023) · cites this paper as [112]
In the citing paper
“In particular, microglial NLRP3 has been shown to be a major driver of amyloid beta and tau toxicity in AD, suggesting its activation has important implications for disease progression (Halle et al, 2008; Venegas et al, 2017; Ising et al, 2019).”
From Mechanisms of DNA damage-mediated neurotoxicity in neurodegenerative disease (2022) · cites this paper as Ising et al, 2019
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Szklarczyk, D., Morris, J. H., Cook, H., Kuhn, M., Wyder, S., Simonovic, M., Santos, A., Doncheva, N. T., Roth, A., Bork, P., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw937 · Cited by 6,980
NLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice
Heneka, M. T., Kummer, M. P., Stutz, A., Delekate, A., Schwartz, S., Vieira-Saecker, A., Griep, A., Axt, D., Remus, A., Tzeng, T.-C., et al. (2013) · Nature · doi:10.1038/nature11729 · Cited by 2,898
Self-citationThe NALP3 inflammasome is involved in the innate immune response to amyloid-β
Halle, A., Hornung, V., Petzold, G. C., Stewart, C. R., Monks, B. G., Reinheckel, T., Fitzgerald, K. A., Latz, E., Moore, K. J., & Golenbock, D. T. (2008) · Nature Immunology · doi:10.1038/ni.1636 · Cited by 2,441
Self-citationDepletion of microglia and inhibition of exosome synthesis halt tau propagation
Asai, H., Ikezu, S., Tsunoda, S., Medalla, M., Luebke, J., Haydar, T., Wolozin, B., Butovsky, O., Kügler, S., & Ikezu, T. (2015) · Nature Neuroscience · doi:10.1038/nn.4132 · Cited by 1,591
Formation of Neurofibrillary Tangles in P301L Tau Transgenic Mice Induced by Aβ42 Fibrils
Götz, J., Chen, F., van Dorpe, J., & Nitsch, R. M. (2001) · Science · doi:10.1126/science.1062097 · Cited by 1,526
Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3
Kanneganti, T., Özören, N., Body–Malapel, M., Amer, A. O., Park, J., Franchi, L., Whitfield, J. R., Barchet, W., Colonna, M., Vandenabeele, P., et al. (2006) · Nature · doi:10.1038/nature04517 · Cited by 1,149
Tau pathology in Alzheimer disease and other tauopathies
Iqbal, K., del C. Alonso, A., Chen, S., Chohan, M. O., El-Akkad, E., Gong, C.-X., Khatoon, S., Li, B., Liu, F., Rahman, A., et al. (2005) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2004.09.008 · Cited by 1,037
Microglia-derived ASC specks cross-seed amyloid-β in Alzheimer’s disease
Venegas, C., Kumar, S., Franklin, B. S., Dierkes, T., Brinkschulte, R., Tejera, D., Vieira-Saecker, A., Schwartz, S., Santarelli, F., Kummer, M. P., et al. (2017) · Nature · doi:10.1038/nature25158 · Cited by 983
Self-citationInflammasome signalling in brain function and neurodegenerative disease
Heneka, M. T., McManus, R. M., & Latz, E. (2018) · Nature Reviews Neuroscience · doi:10.1038/s41583-018-0055-7 · Cited by 836
Self-citationCanonical Nlrp3 Inflammasome Links Systemic Low-Grade Inflammation to Functional Decline in Aging
Youm, Y.-H., Grant, R. W., McCabe, L. R., Albarado, D. C., Nguyen, K. Y., Ravussin, A., Pistell, P., Newman, S., Carter, R., Laque, A., et al. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.09.010 · Cited by 674
Cited by
Sorted by citations
Items 601–700 of 1,003
Gober, R., Dallmeier, J., Davis, D. A., Brzostowicki, D. J., Vaccari, J. P. D. R., Cyr, B. S., Barreda, A., Sun, X., Gultekin, S. H., Garamszegi, S. P., et al. (2024) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlae066 · Cited by 22
Real-Time 3D Imaging and Inhibition Analysis of Various Amyloid Aggregations Using Quantum Dots
Lin, X., Galaqin, N., Tainaka, R., Shimamori, K., Kuragano, M., Noguchi, T. Q. P., & Tokuraku, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21061978 · Cited by 21
Alzheimer’s Disease, Sleep Disordered Breathing, and Microglia: Puzzling out a Common Link
Ulland, T. K., Ewald, A. C., Knutson, A. O., Marino, K. M., Smith, S. M. C., & Watters, J. J. (2021) · Cells · doi:10.3390/cells10112907 · Cited by 21
Liu, D., Zhu, Y., Hou, Z., Wang, H., & Li, Q. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.140885 · Cited by 20
Decoding NLRP3 Inflammasome Activation in Alzheimer’s Disease: A Focus on Receptor Dynamics
Maurya, R., Sharma, A., & Naqvi, S. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-04918-1 · Cited by 22
Glycolytic reprogramming during microglial polarization in neurological diseases
Li, X., Fang, C., Li, Y., Xiong, X., Xu, X., & Gu, L. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1648887 · Cited by 23
TREM2-mediated activation of microglia breaks link between amyloid and tau
Hardy, J., & Salih, D. A. M. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00133-2 · Cited by 21
Chen, P., Bai, Q., Wu, Y., Zeng, Q., Song, X., Guo, Y., Zhou, P., Wang, Y., Liao, X., Wang, Q.-L., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.712907 · Cited by 22
Merighi, S., Nigro, M., Travagli, A., Pasquini, S., Borea, P. A., Varani, K., Vincenzi, F., & Gessi, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23095056 · Cited by 23
Mechanisms of NLRP3 activation and pathology during neurodegeneration
Jose, S., Groves, N. J., Roper, K. E., & Gordon, R. (2022) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2022.106273 · Cited by 22
Fucoidans inhibited tau interaction and cellular uptake
Jin, W., Lu, C., Zhu, Y., Zhao, J., Zhang, W., Wang, L., Linhardt, R. J., Wang, C., & Zhang, F. (2022) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2022.120176 · Cited by 19
An emerging role for stress granules in neurodegenerative disease and hearing loss
Martin, J. L., Dawson, S. J., & Gale, J. E. (2022) · Hearing Research · doi:10.1016/j.heares.2022.108634 · Cited by 23
Johnson, N. H., Kerr, N. A., Vaccari, J. P. D. R., Bramlett, H. M., Keane, R. W., & Dietrich, W. D. (2023) · Translational research · doi:10.1016/j.trsl.2023.02.001 · Cited by 21
The innate immune response in tauopathies
Johnson, A. M., & Lukens, J. R. (2023) · European Journal of Immunology · doi:10.1002/eji.202250266 · Cited by 22
Korhonen, E., Piippo, N., Hytti, M., Hyttinen, J. M. T., Kaarniranta, K., & Kauppinen, A. (2020) · The FASEB Journal · doi:10.1096/fj.201902355rr · Cited by 21
Nutraceutical Compounds Targeting Inflammasomes in Human Diseases
Castejón‐Vega, B., Giampieri, F., & Álvarez-Suárez, J. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21144829 · Cited by 22
Dorion, M., Casas, D., Shlaifer, I., Yaqubi, M., Fleming, P., Karpilovsky, N. C., Chen, C. X. ‐., Nicouleau, M., Piscopo, V. E. C., MacDougall, E. J., et al. (2024) · Molecular Neurodegeneration · doi:10.1186/s13024-024-00723-x · Cited by 22
Mo, X., Cheng, R., Shen, L., Liu, N., Sun, Y., Lin, S., Jiang, G., Li, X., Peng, X., Zhang, Y., et al. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.134939 · Cited by 20
Qi, X., Yuan, S., Ding, J., Sun, W., Shi, Y., Xing, Y., Liu, Z., Yao, Y., Fu, S., Sun, B., et al. (2024) · Aging Cell · doi:10.1111/acel.14352 · Cited by 18
Niu, Q., Li, D., Zhang, J., Piao, Z., Xi, Y., Xi, Y., Kamal, N. N. S. N. M., Li, P., Li, P., & Yin, Y. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102593 · Cited by 19
Targeting tau in Alzheimer’s and beyond: Insights into pathology and therapeutic strategies
Singh, S., Khan, S., Shahid, M., Sardar, M., Hassan, M. I., & Islam, A. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102639 · Cited by 19
Immune Modulation in Alzheimer’s Disease: From Pathogenesis to Immunotherapy
Balkhi, S., Spirito, A. D., Poggi, A. D., & Mortara, L. (2025) · Cells · doi:10.3390/cells14040264 · Cited by 21
Incretin-based therapeutics for the treatment of neurodegenerative diseases
Vear, A., Heneka, M. T., & Clemmensen, C. (2025) · Nature Metabolism · doi:10.1038/s42255-025-01263-4 · Cited by 25
Self-citationTechniques to Study Inflammasome Activation and Inhibition by Small Molecules
Angosto-Bazarra, D., Molina‐López, C., Peñín‐Franch, A., Hurtado‐Navarro, L., & Pelegrín, P. (2021) · Molecules · doi:10.3390/molecules26061704 · Cited by 19
Bi-Directional Relationship Between Autophagy and Inflammasomes in Neurodegenerative Disorders
Panda, C., & Mahapatra, R. K. (2022) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-021-01184-2 · Cited by 20
Dapsone is an anticatalysis for Alzheimer’s disease exacerbation
Lee, J., Kanwar, B. A., Lee, C. J., Sergi, C. M., & Coleman, M. D. (2022) · iScience · doi:10.1016/j.isci.2022.104274 · Cited by 19
Novel Anti-Neuroinflammatory Properties of a Thiosemicarbazone–Pyridylhydrazone Copper(II) Complex
Choo, X. Y., McInnes, L. E., Grubman, A., Wasielewska, J. M., Belaya, I., Burrows, E. L., Quek, H., Cañas-Martín, J., Loppi, S. H., Sorvari, A., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810722 · Cited by 19
Zhang, H., Luo, D., Chen, R., Wang, S., Zhao, Y.-J., Li, J., Zhou, M., Yu, Z., Zhang, J., & Liang, F.-X. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1118508 · Cited by 19
Wang, X. B., Shi, Y.-J., Niu, T.-Y., Chen, T., Li, H.-B., Wu, S., & Li, G.-L. (2023) · Neuroscience Letters · doi:10.1016/j.neulet.2023.137439 · Cited by 18
Neuroinflammation: The Abused Concept
Galea, E., & Graeber, M. B. (2023) · ASN NEURO · doi:10.1177/17590914231197523 · Cited by 21
Evans, F., Alí‐Ruiz, D., Rego, N., Negro‐Demontel, M. L., Lago, N., Cawen, F. A., Pannunzio, B., Sanchez-Molina, P., Reyes, L., Paolino, A., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113269 · Cited by 18
Unravelling the connection between COVID-19 and Alzheimer’s disease: a comprehensive review
Shajahan, S. R., Kumar, S., & Ramli, M. D. C. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1274452 · Cited by 23
Daily, K. P., Badr, A., Eltobgy, M. M., Estfanous, S. Z. K., Whitham, O. D., Tan, M. H., Carafice, C., Krause, K., McNamara, A. J., Hamilton, K., et al. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01390-2 · Cited by 24
Liu, J., Zhang, Z., Zhong, S., Zhang, X., Yang, J., Zhou, Q., Wang, D., Chang, X., & Wang, H. (2024) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2024.175681 · Cited by 21
Mitochondrion-based organellar therapies for central nervous system diseases
Zhao, M., Wang, J., Zhu, S., Wang, M., Chen, C., Wang, L., & Liu, J. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01843-z · Cited by 21
Huang, Z., Xu, P., Hess, D. C., & Zhang, Q. (2024) · Translational Neurodegeneration · doi:10.1186/s40035-024-00457-2 · Cited by 20
Shi, J., Wang, B., Jiang, T., Gao, L., Zhang, Y., & Xu, J. L. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200359 · Cited by 20
Sui, G., Yang, C., Wang, L., Xiong, X., Guo, M., Chen, Z., & Wang, F. (2021) · Metabolic Brain Disease · doi:10.1007/s11011-021-00787-4 · Cited by 19
Inflammasome links traumatic brain injury, chronic traumatic encephalopathy, and Alzheimer’s disease
Seplovich, G., Bouchi, Y., Vaccari, J. P. D. R., Pareja, J. C. M., Reisner, A., Blackwell, L. S., Mechref, Y. S., Wang, K., Tyndall, J. A., Tharakan, B., et al. (2024) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-24-00107 · Cited by 21
NLRP3 inflammasome activation and pyroptosis are dispensable for tau pathology
Paesmans, I., Kolen, K. V., Vandermeeren, M., Shih, P., Wuyts, D., Boone, F., Sanchez, S. G., Grauwen, K., Hauwermeiren, F. V., Opdenbosch, N. V., et al. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1459134 · Cited by 20
Bowles, K. R., Pedicone, C., Pugh, D. A., Oja, L.-M., Sousa, F. H., Keavey, L. K., Fulton-Howard, B., Weitzman, S. A., Liu, Y., Chen, J. L., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.115013 · Cited by 20
Zhou, Y., Huang, Z., Lin, B., Ma, M., Hao, Y., Liu, J., Xu, W., Huang, G., Mo, W., Wang, X., et al. (2025) · Cellular and Molecular Immunology · doi:10.1038/s41423-024-01235-w · Cited by 19
Mammoliti, O., Carbajo, R. J., Pérez‐Benito, L., Yu, X., Prieri, M., Bontempi, L., Embrechts, S., Paesmans, I., Bassi, M., Bhattacharya, A., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c03108 · Cited by 18
Fawzy, M. N., El-Haleim, E. A. A., Zaki, H. F., Salem, H. A., & El‐Sayed, R. M. (2025) · Life Sciences · doi:10.1016/j.lfs.2025.123488 · Cited by 19
Recent Advances in Antibody Therapy for Alzheimer’s Disease: Focus on Bispecific Antibodies
Yang, H. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136271 · Cited by 19
The 2019 yearbook of Neurorestoratology
Huang, H., Chen, L., Mao, G., Bach, J., Xue, Q., Han, F., Guo, X., Otom, A. H., Chernykh, E. R., Alvarez, E. O., et al. (2020) · Journal of Neurorestoratology · doi:10.26599/jnr.2020.9040004 · Cited by 19
Microglia Biomarkers in Alzheimer’s Disease
Zhang, P., Hu, H., Tan, L., & Yu, J. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02348-3 · Cited by 19
Implications for microglial sex differences in tau-related neurodegenerative diseases
Doust, Y. V., King, A. E., & Ziebell, J. M. (2021) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2021.03.010 · Cited by 18
Ni, R. (2021) · Pharmaceuticals · doi:10.3390/ph14111179 · Cited by 18
Deletion of Abi3/Gngt2 influences age-progressive amyloid β and tau pathologies in distinctive ways
Ibanez, K. R., McFarland, K. N., Phillips, J., Allen, M., Lessard, C. B., Zobel, L., De La Cruz, E. G., Shah, S., Vo, Q., Wang, X., et al. (2022) · Alzheimer's Research & Therapy · doi:10.1186/s13195-022-01044-1 · Cited by 18
NLRP3 ‐directed antisense oligonucleotides reduce microglial immunoactivities in vitro
Braatz, C., Komes, M. P., Ravichandran, K. A., de Fragas, M. G., Griep, A., Schwartz, S., McManus, R. M., & Heneka, M. T. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.15778 · Cited by 20
Self-citationZhang, T., Tian, Y., Zheng, X., Li, R., Hu, L., Shui, X., Mei, Y., Wang, Q., Zhang, M., Zheng, X., et al. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14432 · Cited by 17
Amadoro, G., Latina, V., Stigliano, E., & Micera, A. (2023) · Cells · doi:10.3390/cells12222601 · Cited by 20
Muraleedharan, A., & Ray, S. K. (2024) · Brain Sciences · doi:10.3390/brainsci14010096 · Cited by 20
Liu, X., Xiu, C., Zhao, N., Geng, F., Zhu, M., & Ren, Q. (2024) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.13704 · Cited by 20
ATG5 in microglia does not contribute vitally to autoimmune neuroinflammation in mice
Kandadai, K. S., Kotur, M. B., Dokalis, N., Amrein, I., Keller, C. W., Münz, C., Wolfer, D. P., Prinz, M., & Lünemann, J. D. (2021) · Autophagy · doi:10.1080/15548627.2021.1883880 · Cited by 18
Bajracharya, R., Brici, D., Bodea, L., Janowicz, P. W., Götz, J., & Nisbet, R. M. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01147-0 · Cited by 20
An Open Question: Is the A2A Adenosine Receptor a Novel Target for Alzheimer’s Disease Treatment?
Merighi, S., Poloni, T. E., Pelloni, L., Pasquini, S., Varani, K., Vincenzi, F., Borea, P. A., & Gessi, S. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.652455 · Cited by 18
Advances in Genetic and Molecular Understanding of Alzheimer’s Disease
Ibáñez, L., Cruchaga, C., & Fernández, M. V. (2021) · Genes · doi:10.3390/genes12081247 · Cited by 20
Inhibition of NLRP3 alleviated chemotherapy-induced cognitive impairment in rats
Jia, L., Zhou, Y., Ma, L., Li, W., Chan, C., Zhang, S., & Zhao, Y. (2022) · Neuroscience Letters · doi:10.1016/j.neulet.2022.136975 · Cited by 18
Self-citationXiong, W., Xu, K., Sun, J. K.-L., Liu, S., Zhao, B., Shi, J., Herrup, K., Chow, H.-M., Lu, L., & Li, J. (2024) · The EMBO Journal · doi:10.1038/s44318-024-00270-7 · Cited by 17
“In DIV14 or DIV21, cultures were treated with A β 1-42 fi brils in indicated concentrations for 18 h, and cells were collected for subsequent experiments (Ising et al, 2019).”
Song, H., Lee, J., Lee, Y., Kim, S., & Kang, S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26073272 · Cited by 17
Pyroptosis in Alzheimer’s Disease: Mechanisms and Therapeutic Potential
Tang, T. (2025) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-025-01579-5 · Cited by 17
Potential Role of Inflammasomes in Aging
Lee, G., & Lee, G.-S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146768 · Cited by 19
Emerging roles for innate and adaptive immunity in tauopathies
Johnson, A. M., & Lukens, J. R. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.116232 · Cited by 19
Microglia Research in the 100th Year Since Its Discovery
Umpierre, A. D., & Wu, L. (2020) · Neuroscience Bulletin · doi:10.1007/s12264-020-00477-8 · Cited by 19
Ac-YVAD-cmk ameliorated sevoflurane-induced cognitive dysfunction and revised mitophagy impairment
Zheng, D., Wang, H., Zhou, Y., Chen, Y., & Chen, G. (2023) · PLoS ONE · doi:10.1371/journal.pone.0280914 · Cited by 17
Long COVID could become a widespread post-pandemic disease? A debate on the organs most affected
Ferrara, F., Zovi, A., Masi, M., Langella, R., Trama, U., Boccellino, M., & Vitiello, A. (2023) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-023-02417-5 · Cited by 22
Yang, E., Rahim, M. A., Griggs, E., Iban‐Arias, R., & Pasinetti, G. M. (2023) · PNAS Nexus · doi:10.1093/pnasnexus/pgad251 · Cited by 19
Puangmalai, N., Bhatt, N. N., Bittar, A., Jerez, C., Shchankin, N., & Kayed, R. (2023) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2023.102562 · Cited by 17
Self-citationXia, J., Chen, M., Shao, H., Chen, H., Zhu, S., Zhao, M., Luo, W., Yang, J., & Wu, S. (2023) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2812356 · Cited by 17
Sexton, C. E., Bitan, G., Bowles, K. R., Bryś, M., Buée, L., Maina, M. B., Clelland, C. D., Cohen, A. D., Crary, J. F., Dage, J. L., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13533 · Cited by 16
Self-citationImmunological aspects of central neurodegeneration
Niso‐Santano, M., Fuentes, J. M., & Galluzzi, L. (2024) · Cell Discovery · doi:10.1038/s41421-024-00666-z · Cited by 17
Panda, C., Dumka, S., Kumar, S., Gupta, S. K., & Pandey, L. M. (2024) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2024.124917 · Cited by 17
Kodali, M., Madhu, L. N., Somayaji, Y., Attaluri, S., Huard, C., Panda, P. K., Shankar, G., Rao, S., Shuai, B., Gonzalez, J. J., et al. (2024) · Aging Cell · doi:10.1111/acel.14398 · Cited by 18
Yuan, H., Yang, J., Qin, G., Sun, Y., Zhao, C., Wang, C., Ren, J., & Qu, X. (2024) · Chemical Science · doi:10.1039/d4sc04453c · Cited by 17
Torso, M., Ridgway, G. R., Hardingham, I., Schwarz, A. J., & Chance, S. A. (2022) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2022.59 · Cited by 18
Microglia activation linking amyloid-β drive tau spatial propagation in Alzheimer's disease
Wang, Q., & Xie, C. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.951128 · Cited by 20
Fixemer, S., de la Maza, M. M., Hammer, G. P., Jeannelle, F., Schreiner, S., Gérardy, J., Boluda, S., Mirault, D., Mechawar, N., Mittelbronn, M. G. A., et al. (2025) · Acta Neuropathologica · doi:10.1007/s00401-025-02857-8 · Cited by 22
Ayabe, T., Fukuda, T., & Ano, Y. (2020) · Biomolecules · doi:10.3390/biom10010131 · Cited by 17
New Highly Potent NLRP3 Inhibitors: Furanochalcone Velutone F Analogues
Zhang, R., Hong, F., Zhao, M., Cai, X., Jiang, X., Ye, N., Su, K., Li, N., Tang, M., Ma, X., et al. (2022) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.1c00597 · Cited by 16
Kano, N., Ong, G. H., Ori, D., & Kawai, T. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.910654 · Cited by 20
Mild Behavioral Impairment: An Early Sign and Predictor of Alzheimer's Disease Dementia
Jiang, F., Cheng, C., Huang, J., Chen, Q., & Le, W. (2022) · Current Alzheimer Research · doi:10.2174/1567205019666220805114528 · Cited by 18
Recent insights into viral infections as a trigger and accelerator in alzheimer's disease
Vlieger, L. D., Vandenbroucke, R. E., & Hoecke, L. V. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.103340 · Cited by 16
Tau, RNA, and RNA-Binding Proteins: Complex Interactions in Health and Neurodegenerative Diseases
Lester, E., & Parker, R. (2023) · The Neuroscientist · doi:10.1177/10738584231154551 · Cited by 16
Wang, Y., Wu, T. Z., Tsai, M., Rezzonico, M. G., Abdel‐Haleem, A. M., Xie, L., Gandham, V. D., Ngu, H., Stark, K. L., Glock, C., et al. (2023) · eLife · doi:10.7554/elife.83451 · Cited by 16
Monoclonal antibody therapy for Alzheimer's disease focusing on intracerebral targets
Gu, X., Long, Q., Qi, Q., Zhou, J., Chen, S., & Wang, L. (2024) · BioScience Trends · doi:10.5582/bst.2023.01288 · Cited by 17
Unveiling the role of iPLA2β in neurodegeneration: From molecular mechanisms to advanced therapies
Liu, J., Tan, J., Tang, B., & Guo, J. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107114 · Cited by 18
Tau, synapse loss and gliosis progress in an Alzheimer’s mouse model after amyloid-β immunotherapy
Welikovitch, L. A., de Gérando, A. M., Khasnavis, A., Bhavsar, H., Meltzer, J. C., Buée, L., Chibnik, L. B., Bussière, T., & Hyman, B. T. (2024) · Brain · doi:10.1093/brain/awae345 · Cited by 16
Self-citationIdentification and development of cGAS inhibitors and their uses to treat Alzheimer's disease
Alarcón‐Espósito, J., Nagiri, R. K., Gan, L., & Sinha, S. C. (2025) · Neurotherapeutics · doi:10.1016/j.neurot.2025.e00536 · Cited by 16
NLRP3 Is Involved in the Maintenance of Cerebral Pericytes
Quan, W., Luo, Q., Tang, Q., Furihata, T., Li, D., Fassbender, K. C., & Liu, Y. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00276 · Cited by 17
Positron Emission Tomography in Animal Models of Tauopathies
Cao, L., Kong, Y., Ji, B., Ren, Y., Guan, Y., & Ni, R. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.761913 · Cited by 14
The Role of Immunity in Alzheimer's Disease
McManus, R. M. (2022) · Advanced Biology · doi:10.1002/adbi.202101166 · Cited by 16
Self-citationLu, Y., Xu, K., Lin, D., Wang, S., Fu, R., Deng, X., Croppi, G., & Zhang, J. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.964429 · Cited by 18
Hallmarks of NLRP3 inflammasome activation are observed in organotypic hippocampal slice culture
Hoyle, C., Redondo‐Castro, E., Cook, J., Tzeng, T.-C. J., Allan, S. M., Brough, D., & Lemarchand, E. (2020) · Immunology · doi:10.1111/imm.13221 · Cited by 17
Ren, Y., Wu, K., He, Y., Zhang, H., Ma, J., Li, C., Ruan, Y., Zhang, J., Wen, Y., Wu, X., et al. (2024) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2024.117183 · Cited by 17
Barbera, L. L., Krashia, P., Loffredo, G., Cauzzi, E., Paolis, M. L. D., Montanari, M., Saba, L., Spoleti, E., Ficchì, S., Zaccone, C., et al. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00893-2 · Cited by 17
Gaire, B. P., Koronyo, Y., Vit, J., Hutton, A., Subedi, L., Fuchs, D.-T. S., Swerdlow, N., Rentsendorj, A., Shahin, S., Martinon, D., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-68580-4 · Cited by 16
Sun, L., Ouyang, J., Zeng, Z., Zeng, C., Ma, Y., Zeng, F., & Wu, S. (2021) · Bioactive Materials · doi:10.1016/j.bioactmat.2021.08.010 · Cited by 15
Wang, Y., Tang, Y., Gao, X. W., Zhang, N., Lv, Q., Liu, J., & Li, Y. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.971136 · Cited by 15
Metadata
- Authors
- Ising, C., Venegas, C., Zhang, S., Scheiblich, H., Schmidt, S. V., Vieira-Saecker, A., Schwartz, S., Albasset, S., McManus, R. M., Tejera, D., Griep, A., Santarelli, F., Brosseron, F., Opitz, S., Stunden, J., Merten, M., Kayed, R., Golenbock, D. T., Blum, D., Latz, E., Buée, L., & Heneka, M. T.
- Affiliations
- University Hospital Bonn (DE)
- German Center for Neurodegenerative Diseases (DE)
- The University of Texas Medical Branch at Galveston (US)
- University of Massachusetts Chan Medical School (US)
- Inserm (FR)
- Corresponding author
- Heneka, Michael T.
- ORCID
- Venue
- Nature
- Published
- 2019-11-20
- Volume
- 575
- Issue
- 7784
- Pages
- 669-673
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC7324015
- OpenAlex
- W2990312754
- Semantic Scholar
- 6a9d745a33a2d013c621f57586d9d719671530a7
- Cited by
- 1,487
- References
- 28
- Citations by year
- 2026: 189 · 2025: 226 · 2024: 255 · 2023: 226 · 2022: 248 · 2021: 193 · 2020: 143 · 2019: 3
- FWCI
- 101.29
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Open Repository and Bibliography (University of Luxembourg) (submittedVersion, other-oa)
- HAL (submittedVersion, other-oa)
- RePEc: Research Papers in Economics (submittedVersion)
- Institutional Repository of the University of Granada (University of Granada) (submittedVersion, cc-by-nc-nd)
- DZNE Pub (submittedVersion)
- Funders
- Deutsche Forschungsgemeinschaft (R01 AG059752-02)
- Agence Nationale de la Recherche (ANR-11-LABX-0009)
- Deutsches Zentrum für Neurodegenerative Erkrankungen
- National Institutes of Health
- National Institute on Aging (R01AG059752, R01AG054025)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- NLRP3 inflammasome, tau hyperphosphorylation, tau aggregation, neurofibrillary tangles, Alzheimer's disease, amyloid-beta, microglia, amyloid hypothesis, frontotemporal dementia, neuroinflammation, caspase-1, IL-1β
- MeSH terms
- NLR Family, Pyrin Domain-Containing 3 Protein, Animals, Gene Expression Regulation, Humans, Mice, Inbred C57BL, Phosphorylation, tau Proteins, Microglia, Cyclin-Dependent Kinase 5, Mice, Inflammasomes, Protein Aggregation, Pathological
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
